# A Trial of Tisotumab Vedotin in Cervical Cancer

> **NCT03438396** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 102 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** tisotumab vedotin

## Key facts

- **NCT ID:** NCT03438396
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-12
- **Primary completion:** 2020-02-06
- **Final completion:** 2022-08-02
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2023-07-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03438396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03438396, "A Trial of Tisotumab Vedotin in Cervical Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03438396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*